The detection of circulating breast cancer cells in blood

Gilbey, A M; Burnett, Dave; Coleman, Rob; Holen, Ingunn

doi:10.1136/jcp.2003.013755

Cited by 82 publications

(95 citation statements)

References 84 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…RT-PCR has been used for the detection of specific tumour cell markers, thus indicating the presence of circulating breast tumour cells in the blood, with varying degrees of sensitivity and specificity [33]. The hMAM gene was described to be a potentially specific marker for the detection of circulating breast cancer cells [34].…”

Section: Discussionmentioning

confidence: 99%

Detection of human mammaglobin mRNA in serial peripheral blood samples from patients with non-metastatic breast cancer is not predictive of disease recurrence

Marques

Teixeira

Diamond

et al. 2008

Breast Cancer Res Treat

View full text Add to dashboard Cite

International audienceHuman mammaglobin (hMAM) mRNA is a sensitive and specific marker of breast cancer cells. We evaluated if hMAM mRNA detection in serial peripheral blood samples from non-metastatic breast cancer patients predicts for disease recurrence. Patients scheduled for adjuvant or neoadjuvant chemotherapy were eligible. Serial blood samples were collected up to 5 years, the first before (neo)adjuvant chemotherapy. hMAM gene expression was analysed by RT-PCR. Specificity was evaluated in blood samples from healthy volunteers. A total of 321 patients were included. The incidence of pre-chemotherapy hMAM-positive samples was similar in patients who latter experienced cancer recurrence (22.4%) and those who remained disease-free (17.9%; = 0.46). Similarly, the mean number of positive follow-up samples was similar in both groups (0.15 ± 0.22 and 0.13 ± 013; = 0.29). Furthermore, there was no difference in disease-free (= 0.63) or overall survival (= 0.57) in patients with and without positive baseline samples or between patients whose follow-up samples were always hMAM negative and those with at least one positive sample. Multivariate survival analysis confirmed that hMAM mRNA detection before or after (neo)adjuvant chemotherapy was not predictive of recurrence. There is no evidence that hMAM mRNA detection at diagnosis or during follow-up predicts for breast cancer recurrence

show abstract

Section: Discussionmentioning

confidence: 99%

Detection of human mammaglobin mRNA in serial peripheral blood samples from patients with non-metastatic breast cancer is not predictive of disease recurrence

Marques

Teixeira

Diamond

et al. 2008

Breast Cancer Res Treat

View full text Add to dashboard Cite

show abstract

“…Metastatic disease occurs as a result of a series of steps involving multiple host-tumor interactions [4] (reviewed by Gilbey et al [5]). Primary tumor cells, whether they possess genetic mutations or have certain stem-like properties, grow aberrantly and may eventually detach, intravasate into the lymphatic and/or blood systems, before developing into secondary disease A. M. Friel Á C. Corcoran Á L. O'Driscoll (&) [4].…”

Section: Breast Cancer Recurrencementioning

confidence: 99%

Relevance of circulating tumor cells, extracellular nucleic acids, and exosomes in breast cancer

Friel

Corcoran

Crown

et al. 2010

Breast Cancer Res Treat

View full text Add to dashboard Cite

Early detection of cancer is vital to improved overall survival rates. At present, evidence is accumulating for the clinical value of detecting occult tumor cells in peripheral blood, plasma, and serum specimens from cancer patients. Both molecular and cellular approaches, which differ in sensitivity and specificity, have been used for such means. Circulating tumor cells and extracellular nucleic acids have been detected within blood, plasma, and sera of cancer patients. As the presence of malignant tumors are clinically determined and/or confirmed upon biopsy procurement-which in itself may have detrimental effects in terms of stimulating cancer progression/metastases-minimally invasive methods would be highly advantageous to the diagnosis and prognosis of breast cancer and the subsequent tailoring of targeted treatments for individuals, if reliable panels of biomarkers suitable for such an approach exist. Herein, we review the current advances made in the detection of such circulating tumor cells and nucleic acids, with particular emphasis on extracellular nucleic acids, specifically extracellular mRNAs and discuss their clinical relevance.

show abstract

“…The sensitivity of RT-PCR has already been reported for detection of disseminated breast cancer cells; for each marker at a density of approximately 1-5 cancer cells per 1-5 ml of blood has been used [21].…”

Section: Reverse Transcriptase Polymerase Chain Reactions (Rt-pcr)mentioning

confidence: 99%

Molecular Markers in Peripheral Blood of Iranian Women with Breast Cancer

Oloomi

Bouzari

Mohagheghi

et al. 2012

Cancer Microenvironment

View full text Add to dashboard Cite

A biomarker is a quantifiable laboratory measure of a disease specific biologically relevant molecule that can act as an indicator of a current or future disease state. The purpose of this study is to detect the expression of RNA biomarkers using Cytokeratin 19 (CK-19), Mammaglobin (MAM), Carcinoembryonic antigen (CEA), Mucin (MUC), C-Myc, erb-B2, a proliferation marker (Ki-67), Epidermal growth factor receptor (Her2/neu) and Estrogen receptor (ER) in Iranian women who were diagnosed with breast cancer. In this study, 90 samples; 60 cancer patients and 30 healthy controls were considered. 73.4 % patients were in stage I/II and 26.6 % were in stage III/IV. Patients were selected prior to the administration of any adjuvant systemic therapy. Total RNA extraction was obtained from peripheral blood of each patient and healthy control. Reverse transcription polymerase chain reaction (RT-PCR) method was used for detection of mRNA of the selected biomarkers of circulating breast cancer cells in blood. Molecular characterization is assessed as a method for early detection of breast cancer. For this purpose, eleven specific primers were selected and RT-PCR was used. The data of RT-PCR revealed that expression of MUC1, CK19, CEA, MAM, erbB-2, Ki67 and C-Myc biomarkers were significantly different between breast cancer patients and healthy controls. On the other hand, ERα, ERβ and Her2 markers were not significantly different between the two mentioned groups.

show abstract

The detection of circulating breast cancer cells in blood

Cited by 82 publications

References 84 publications

Detection of human mammaglobin mRNA in serial peripheral blood samples from patients with non-metastatic breast cancer is not predictive of disease recurrence

Detection of human mammaglobin mRNA in serial peripheral blood samples from patients with non-metastatic breast cancer is not predictive of disease recurrence

Relevance of circulating tumor cells, extracellular nucleic acids, and exosomes in breast cancer

Molecular Markers in Peripheral Blood of Iranian Women with Breast Cancer

Contact Info

Product

Resources

About